Objectives Detection of recurrent disease is essential for treatment planning in patients with paraganglioma. The aim of this study was to compare I-123-metaiodobenzylguanidine (I-123-MIBG) scintigraphy [whole-body and single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (F-18-DOPA PET-CT) in the re-staging of patients with known or suspected recurrent paraganglioma. Methods Twelve patients with known or suspected recurrent paraganglioma after initial surgery were included in the study. F-18-DOPA PET-CT and I-123-MIBG scintigraphy (whole-body and SPECT-CT scanning) were performed in all patients; the results were compared on a per patient and a per lesion basis. Cytohistology (when available) and a combination of laboratory and imaging studies and follow-up were used as reference standard; any modification in treatment planning was recorded. In all cases recurrent disease (local or distant) was confirmed by cytohistology (four cases) or at subsequent follow-up (eight cases). Results All patients had positive F-18-DOPA studies (100% sensitivity) whereas nine had positive I-123-MIBG studies (75% sensitivity; P = not significant). F-18-DOPA detected 98% of lesions, whereas 38% were detected with I-123-MIBG (P = 0.04). F-18-DOPA showed more lesions than I-123-MIBG in eight patients; both techniques showed the same number of lesions in two cases whereas in two patients I-123-MIBG showed a greater number of lesions. A change in treatment planning was suggested by F-18-DOPA in one patient. Conclusion These data support the superiority of F-18-DOPA PET-CT over I-123-MIBG scintigraphy to assess disease extension in patients with recurrent paraganglioma; however, in cases with inoperable disease, I-123-MIBG maintains a unique role in allowing the selection of patients suitable for I-131-MIBG therapy. Nucl Med Commun 32:575-582 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Comparison of I-123-MIBG SPECT-CT and F-18-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma
Corsello S;
2011-01-01
Abstract
Objectives Detection of recurrent disease is essential for treatment planning in patients with paraganglioma. The aim of this study was to compare I-123-metaiodobenzylguanidine (I-123-MIBG) scintigraphy [whole-body and single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (F-18-DOPA PET-CT) in the re-staging of patients with known or suspected recurrent paraganglioma. Methods Twelve patients with known or suspected recurrent paraganglioma after initial surgery were included in the study. F-18-DOPA PET-CT and I-123-MIBG scintigraphy (whole-body and SPECT-CT scanning) were performed in all patients; the results were compared on a per patient and a per lesion basis. Cytohistology (when available) and a combination of laboratory and imaging studies and follow-up were used as reference standard; any modification in treatment planning was recorded. In all cases recurrent disease (local or distant) was confirmed by cytohistology (four cases) or at subsequent follow-up (eight cases). Results All patients had positive F-18-DOPA studies (100% sensitivity) whereas nine had positive I-123-MIBG studies (75% sensitivity; P = not significant). F-18-DOPA detected 98% of lesions, whereas 38% were detected with I-123-MIBG (P = 0.04). F-18-DOPA showed more lesions than I-123-MIBG in eight patients; both techniques showed the same number of lesions in two cases whereas in two patients I-123-MIBG showed a greater number of lesions. A change in treatment planning was suggested by F-18-DOPA in one patient. Conclusion These data support the superiority of F-18-DOPA PET-CT over I-123-MIBG scintigraphy to assess disease extension in patients with recurrent paraganglioma; however, in cases with inoperable disease, I-123-MIBG maintains a unique role in allowing the selection of patients suitable for I-131-MIBG therapy. Nucl Med Commun 32:575-582 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
